Tuesday, July 30, 2019

Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move: Special Interview with Trevor Peters of Willow Biosciences (CSE: $WLLW.C) (OTC: $CANSF)

Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move: Special Interview with Trevor Peters of Willow Biosciences (CSE: $WLLW.C) (OTC: $CANSF)

Delta, Kelowna, BC –July 30, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca  release today’s edition of Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

Read this in full at

In today’s podcast we interview Trevor Peters, President and CEO of Willow Biosciences Inc. (CSE: WLLW) (OTC: CANSF), regarding the company’s entrance into the cannabinoid space, some of their recent developments as well as the future of the CBD market.

Mr. Peters has co-founded four start-up companies in the past 15 years and raised over $1.0 billion in equity and debt financing at various stages of corporate development and has been integral to successful transactions totalling over $4.0 billion on sale. Mr. Peters previously was Chief Financial Officer at Caracal Energy Inc., which sold to Glencore plc in 2014 for $1.8 billion.

Willow Biosciences was founded in 2019 through the merger of BIOCAN Technologies: a team of experienced executives from Calgary and researchers from the University of British Columbia, and Epimeron: a team of researchers from the University of Calgary in Alberta, Canada.
The company has developed the only fully-integrated synthetic biology solution for opiate biosynthesis and are now leveraging their unique design-build process–and our proven track record–to the biosynthesis of cannabinoids.
We discussed the company’s last announcement of their partnership with Noramco to collaboratively develop a yeast-based biosynthesis platform for the production and distribution of CBD.
“Noramco sees the market the same way we do. There selling about 1 tonne of CBD into the pharmaceutical market. Once we see descheduling in the US, we will see them selling more broadly into those markets. Noramco currently uses chemical synthesis which is more expensive then our process which is why they’ve partnered with us exclusively. They view our process as being roughly 80% more cost effective then their existing processes. Noramco is important to us because they’re one of the world’s most sophisticated and largest manufacturers of controlled substances and API’s and they already have a very large customer base.” 
 Trevor also expressed the company’s interest in exploring the culturing of other cannabinoids in the future such as CBG, THC and THCV.
Trevor also discussed the major differences between his company which biosynthetically cultures plant molecules and the plant cultivation and extract community and some of the benefit of cultured CBD versus plant extracted molecules.
“Our CBD molecule is the same as the one the plant produces, except when we produce it it’s just CBD, and is obviously very high purity from that perspective. It’s consistent. There’s no extract process, or other distillation process associated with it, it comes out in the final form. It’s very usable in whatever market might be required.”
Willow Biosciences is not the only company looking into cultured CBD as we saw mostly recently from Cronos Group (NASDAQ: CRON) (TSX:CRON) and their  announcement to enter into an agreement to acquire GMP compliant fermentation and manufacturing facility from Apotex Fermentation. This follows Cronos Grouppartnership with Ginkgo Bioworks with the aim to produce cultured cannabinoids and with this new facility addition, the company would be able to achieve that at a commercial scale.

When asked about the future of Willow Biosciences Trevor commented, “over the next 6 to 12 months we are going to be working on the hardcore science, developing a new strain and being able to take it to scale and manufacturing. Since the Noramco announcement we’ve seen a lot of interest from companies that are interested in accessing CBD at scale. We’ve also seen other interests from people in the pharmacological community looking at minor cannabinoids as well.”

Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com  website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment   

Subscribe to the new cannabis podcast series:

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes,  Spotify, Google Play Music, Stitcher, Spreaker,   YouTube via Spreaker,  iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and  sector trends  from Investorideas.com with our news alerts , articles , podcasts and videos  talking about cannabis,  crypto,  technology including  AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change Podcast and  the AI Eye Podcast and column covering developments in AI. 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Follow us on Social Media

Contact Investorideas.com


Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directories

No comments:

Post a Comment